India, June 1 -- Stock of Jade Biosciences, Inc. (JBIO) is dropping about 12 percent in Monday morning trading despite the company's positive report from a Phase 1 trial evaluating JADE101 for the treatment of immunoglobulin A nephropathy.
The company's stock is currently trading at $18.35, down 12.77 percent or $2.69, over the previous close of $21.04 on the Nasdaq. It has traded between $6.57 and $28.00 in the past one year.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....